Skip to main content
    A

    Arcturus Therapeutics Holdings Inc (ARCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.97
    -0.34 (-4.09%)

    Market Cap: $240.96M

    Last updated: Nov 17, 2026 at 4:34 PM ET

    Arcturus Therapeutics Holdings Inc (ARCT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Arcturus Therapeutics Holdings (ARCT) has a market cap of $240.96M and an enterprise value of $56.14M. It kept -285.91% of revenue as net income over the last 12 months. Revenue fell 68.74% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 76.70% below the market cap, as cash exceeds debt.

    Market Cap$240.96M
    Enterprise Value$56.14M
    Latest price (Nov 17, 2026)$7.97

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.06% in the quarter ended Sep 30, 2026 and grew 2.51% a year over 2 years.

    Shares Outstanding28.44M
    Shares Change (YoY)+4.60%
    Shares Change (QoQ)+0.06%
    Share Count Growth (2Y CAGR)+2.51%

    Valuation Ratios

    Sales and book value multiples are 7.4x and 1.3x. Its year-end P/S ranged from 1.9x to 88.0x from 2017 to 2025.

    P/S Ratio7.4x
    Forward P/S8.6x
    P/B Ratio1.3x

    Valuation history and multiples

    Price Statistics

    The stock is up 9.63% over 52 weeks and trades 34.30% below its 50-day average.

    Beta (1Y)2.07
    52-Week Change+9.63%
    1-Month Change-23.51%
    3-Month Change-22.47%
    6-Month Change+19.13%
    5-Year Change-75.46%
    10-Year Change-17.91%
    Total Return (1Y)+9.63%
    Total Return (3Y CAGR)-31.67%
    Total Return (5Y CAGR)-26.76%
    Return vs SPY (1Y)+8.83%
    Max Drawdown (1Y)-52.92%
    Max Drawdown (3Y)-87.54%
    Sharpe Ratio (1Y)0.23
    Correlation with SPY (1Y)0.36
    50-Day Average$12.13
    200-Day Average$9.11
    52-Week Range$5.50 to $17.96
    RSI (14 Days)35.2
    Average Volume (20 Days)674.26K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.68x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.68x
    Quick Ratio6.68x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -51.71% over the last 12 months, against a 5-year average of -32.16%.

    Return on Equity (ROE)-51.71%
    Return on Assets (ROA)-40.52%
    ROE (5Y Average)-32.16%
    ROA (5Y Average)-20.90%
    ROIC (5Y Average)-25.57%
    Asset Turnover0.12x
    Receivables Turnover19.93x

    Scores

    ARCT has an Altman Z-Score of -1.19, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.19
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $30.51M over the last 12 months.

    Revenue$30.51M
    Revenue Growth (YoY)-68.74%
    Gross Profit$30.51M
    Operating Income-$94.97M
    Pretax Income-$87.25M
    Net Income-$87.24M
    Reported EPS (TTM)-$3.08

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 78.36% of the $215.32M in total assets.

    Cash and Equivalents$184.82M
    Total Debt$0
    Net Cash$184.82M
    Net Cash Per Share$6.50
    Working Capital$161.05M
    Shareholder Equity$168.73M
    Book Value Per Share$5.93
    Total Assets$215.32M
    Total Liabilities$46.59M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$62.48M
    FCF Per Share-$2.20
    Depreciation and Amortization$2.58M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -311.22%.

    Gross Margin100.00%
    Operating Margin-311.22%
    Pretax Margin-285.92%
    Net Margin-285.91%

    Growth

    Revenue fell 26.43% a year over 3 years.

    Revenue Growth (3Y CAGR)-26.43%
    Revenue Growth (5Y CAGR)+53.78%
    Book Value Per Share Growth (2Y CAGR)-13.57%
    Tangible Book Per Share Growth (2Y CAGR)-13.57%

    Revenue and profit by year

    Dividends and Yields

    ARCT does not pay a dividend.

    Buyback Yield-5.26%
    Shareholder Yield-5.26%

    Stock Splits

    The last split was a 1-for-7 reverse split on Nov 16, 2017.

    Last Split DateNov 16, 2017
    Split TypeReverse split
    Split Ratio1:7

    Peer Position

    Against 7 similar companies, ARCT has the 3rd highest P/S.

    P/S Ratio7.4x vs 5.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)-68.74% vs -88.51% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -37.45% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-37.45%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ARCT

    What is ARCT's market cap?

    Arcturus Therapeutics Holdings has a market cap of $240.96M. Its enterprise value, which adds debt and subtracts cash, is $56.14M.

    How many shares of ARCT are outstanding?

    Arcturus Therapeutics Holdings has 28.44M shares outstanding. The count is up 4.60% from a year earlier.

    Does ARCT pay a dividend?

    No. Arcturus Therapeutics Holdings does not pay a dividend.

    How much debt does ARCT have?

    Arcturus Therapeutics Holdings has $0 of total debt and $184.82M of cash and equivalents, a net cash position of $184.82M.